Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru


ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Лечебное дело
2021 / N 3

Ведение пациентов с подагрой: фокус на поражение почек
А.А. Кондрашов, А.А. Клименко, Н.А. Шостак

Список литературы

1. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Current Opinion in Rheumatology 2014 Mar;26(2):186-91.
2. Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clinical Rheumatology 2020 Apr;39(4):1061-3.
3. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective – a review. Journal of Advanced Research 2017 Sep;8(5):495-511.
4. Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease study. Rheumatology (Oxford, England) 2020 Jul;59(7):1529-38.
5. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nature Reviews. Disease Primers 2019 Sep;5(1):69.
6. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews. Rheumatology 2020 Jul;16(7):380-90.
7. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism 2020 Jun;50(3S):S11-6.
8. Kuo CF, Luo SF. Risk of premature death in gout unchanged for years. Nature Reviews. Rheumatology 2017 Apr;13(4):200-1.
9. Hill NR, Fatoba, ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS One 2016 Jul;11(7):e0158765.
10. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Research & Therapy 2015 Apr;17(1):1-12.
11. Mehta TH, Goldfarb DS. Uric acid stones and hyperuricosuria. Advances in Chronic Kidney Disease 2012 Nov;19(6):413-8.
12. Johnson RJ. Why focus on uric acid? Current Medical Research and Opinion 2015;31(Suppl 2):3-7.
13. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Seminars in Nephrology 2011 Sep;31(5):447-52.
14. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002 Dec;13(12):2888-97.
15. Hovind P, Rossing P, Johnson RJ, Parving HH. Serum uric acid as a new player in the development of diabetic nephropathy. Journal of Renal Nutrition 2011 Jan;21(1):124-7.
16. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Seminars in Nephrology 2011 Sep;31(5):459-65.
17. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Annals of the Rheumatic Diseases 2015 Apr;74(4):661-7.
18. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine 2017;15(1):123.
19. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nature Reviews. Rheumatology 2014 Nov;10(11):654-61.
20. Lu CC, Wu SK, Chen HY, Chung WS, Lee MC, Yeh CJ. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. The Journal of Rheumatology 2014 Sep;41(9):1878-83.
21. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PloS One 2012;7(11):e50046.
22. Jing J, Kielstein, JT, Schultheiss UT, Sitter T, Titze S, Schaeffner ES, McAdams-DeMarco M, Kronenberg F, Eckardt KU, Köttgen A; GCKD Study Investigators. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrology, Dialysis, Transplantation 2015 Apr;30(4):613-21.
23. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination survey, 2007–2016. Arthritis & Rheumatology (Hoboken, N.J.) 2019 Jun;71(6):991-9.
24. Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. American Journal of Kidney Diseases 2017 Sep;70(3):422-39.
25. Stewart S, Tallon A, Taylor WJ, Gaffo A, Dalbeth N. How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials. Seminars in Arthritis and Rheumatism 2020 Apr;50(2):303-13.
26. Stamp L, Taylor W, Gaffo A; Gout and Crystal Arthritis Network. Variability in urate lowering therapy prescribing: a Gout, hyperuricaemia and Crystal-Associated disease Network (G-CAN) physician survey. The Journal of Rheumatology 2021 Jan;48(1):152-3.
27. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, L Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz FP, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases 2017 Jan;76(1):29-42.
28. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald T, Nuki G, Pywell A, Zhang W, Roddy E; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford, England) 2017 Jul;56(7):e1-20.
29. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt C, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research 2020 Jun;72(6):744-60.
30. Министерство здравоохранения РФ; Ассоциация ревматологов России. Подагра. Клинические рекомендации. МКБ 10: М10.0/М10.1/М10.2/М10.3/М10.4/М10.9. Год утверждения (частота пересмотра): 2018 (1 раз в 3 года). М., 2018. 49 с.
31. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis and Rheumatism 2012 Aug;64(8):2529-36.
32. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford, England) 2009 Feb;48(2):188-94.
33. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The Journal of Rheumatology 2009 Jun;36(6):1273-82.
34. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgraduate Medicine 2013 Jan;125(1):106-14.
35. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. Journal of Clinical Rheumatology 2011 Jan;17(1):7-13.
36. Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis and Rheumatology 2016;68(8):2035-43.
37. Perez-Ruiz F, Calabozo M, Herrero-Beites A, García-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricaemia and gouty bouts. Nephron 2000 Nov;86(3):287-91.
38. Ohno I, Ichida K, Okabe H, Hikita M, Uetake D, Kimura H, Saikawa H, Hosoya T. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Internal Medicine (Tokio, Japan) 2005 Jul;44(7):706-9.
39. Ejaz AA, Nakagawa T, Kanbay M, Kuwabara M, Kumar A, Arroyo FEG, Roncal-Jimenez C, Sasai F, Kang DH, Jensen T, Hernando AA, Rodriguez-Iturbe B, Garcia G, Tolan DR, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ. Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage. Seminars in Nephrology 2020 Nov;40(6):574-85.
40. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology 2015 Apr;16:58.
41. Foody JA, Turpin RS, Tidwell BA, Lawrence D, Schulman KL. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. American Health & Drug Benefits 2017 Nov;10(8):393-401.
42. Gao L, Wang B, Pan Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clinical Cardiology 2021 Jul;44(7):907-16.

References

1. Bardin T, Richette P. Definition of hyperuricemia and gouty conditions. Current Opinion in Rheumatology 2014 Mar;26(2):186-91.
2. Mattiuzzi C, Lippi G. Recent updates on worldwide gout epidemiology. Clinical Rheumatology 2020 Apr;39(4):1061-3.
3. Ragab G, Elshahaly M, Bardin T. Gout: an old disease in new perspective – a review. Journal of Advanced Research 2017 Sep;8(5):495-511.
4. Xia Y, Wu Q, Wang H, Zhang S, Jiang Y, Gong T, Xu X, Chang Q, Niu K, Zhao Y. Global, regional and national burden of gout, 1990–2017: a systematic analysis of the Global Burden of Disease study. Rheumatology (Oxford, England) 2020 Jul;59(7):1529-38.
5. Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F, Stamp LK. Gout. Nature Reviews. Disease Primers 2019 Sep;5(1):69.
6. Dehlin M, Jacobsson L, Roddy E. Global epidemiology of gout: prevalence, incidence, treatment patterns and risk factors. Nature Reviews. Rheumatology 2020 Jul;16(7):380-90.
7. Singh JA, Gaffo A. Gout epidemiology and comorbidities. Seminars in Arthritis and Rheumatism 2020 Jun;50(3S):S11-6.
8. Kuo CF, Luo SF. Risk of premature death in gout unchanged for years. Nature Reviews. Rheumatology 2017 Apr;13(4):200-1.
9. Hill NR, Fatoba, ST, Oke JL, Hirst JA, O’Callaghan CA, Lasserson DS, Hobbs FDR. Global prevalence of chronic kidney disease – a systematic review and meta-analysis. PloS One 2016 Jul;11(7):e0158765.
10. Roughley MJ, Belcher J, Mallen CD, Roddy E. Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies. Arthritis Research & Therapy 2015 Apr;17(1):1-12.
11. Mehta TH, Goldfarb DS. Uric acid stones and hyperuricosuria. Advances in Chronic Kidney Disease 2012 Nov;19(6):413-8.
12. Johnson RJ. Why focus on uric acid? Current Medical Research and Opinion 2015;31(Suppl 2):3-7.
13. Kang DH, Chen W. Uric acid and chronic kidney disease: new understanding of an old problem. Seminars in Nephrology 2011 Sep;31(5):447-52.
14. Kang DH, Nakagawa T, Feng L, Watanabe S, Han L, Mazzali M, Truong L, Harris R, Johnson RJ. A role for uric acid in the progression of renal disease. Journal of the American Society of Nephrology 2002 Dec;13(12):2888-97.
15. Hovind P, Rossing P, Johnson RJ, Parving HH. Serum uric acid as a new player in the development of diabetic nephropathy. Journal of Renal Nutrition 2011 Jan;21(1):124-7.
16. Jalal DI, Maahs DM, Hovind P, Nakagawa T. Uric acid as a mediator of diabetic nephropathy. Seminars in Nephrology 2011 Sep;31(5):459-65.
17. Kuo CF, Grainge MJ, Mallen C, Zhang W, Doherty M. Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study. Annals of the Rheumatic Diseases 2015 Apr;74(4):661-7.
18. Bardin T, Richette P. Impact of comorbidities on gout and hyperuricaemia: an update on prevalence and treatment options. BMC Medicine 2017;15(1):123.
19. Richette P, Perez-Ruiz F, Doherty M, Jansen TL, Nuki G, Pascual E, Punzi L, So AK, Bardin T. Improving cardiovascular and renal outcomes in gout: what should we target? Nature Reviews. Rheumatology 2014 Nov;10(11):654-61.
20. Lu CC, Wu SK, Chen HY, Chung WS, Lee MC, Yeh CJ. Clinical characteristics of and relationship between metabolic components and renal function among patients with early-onset juvenile tophaceous gout. The Journal of Rheumatology 2014 Sep;41(9):1878-83.
21. Krishnan E. Reduced glomerular function and prevalence of gout: NHANES 2009-10. PloS One 2012;7(11):e50046.
22. Jing J, Kielstein, JT, Schultheiss UT, Sitter T, Titze S, Schaeffner ES, McAdams-DeMarco M, Kronenberg F, Eckardt KU, Köttgen A; GCKD Study Investigators. Prevalence and correlates of gout in a large cohort of patients with chronic kidney disease: the German Chronic Kidney Disease (GCKD) study. Nephrology, Dialysis, Transplantation 2015 Apr;30(4):613-21.
23. Chen-Xu M, Yokose C, Rai SK, Pillinger MH, Choi HK. Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination survey, 2007–2016. Arthritis & Rheumatology (Hoboken, N.J.) 2019 Jun;71(6):991-9.
24. Vargas-Santos AB, Neogi T. Management of gout and hyperuricemia in CKD. American Journal of Kidney Diseases 2017 Sep;70(3):422-39.
25. Stewart S, Tallon A, Taylor WJ, Gaffo A, Dalbeth N. How flare prevention outcomes are reported in gout studies: a systematic review and content analysis of randomized controlled trials. Seminars in Arthritis and Rheumatism 2020 Apr;50(2):303-13.
26. Stamp L, Taylor W, Gaffo A; Gout and Crystal Arthritis Network. Variability in urate lowering therapy prescribing: a Gout, hyperuricaemia and Crystal-Associated disease Network (G-CAN) physician survey. The Journal of Rheumatology 2021 Jan;48(1):152-3.
27. Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, L Jansen TL, Janssens H, Lioté F, Mallen C, Nuki G, Perez-Ruiz FP, Pimentao J, Punzi L, Pywell T, So A, Tausche AK, Uhlig T, Zavada J, Zhang W, Tubach F, Bardin T. 2016 updated EULAR evidence-based recommendations for the management of gout. Annals of the Rheumatic Diseases 2017 Jan;76(1):29-42.
28. Hui M, Carr A, Cameron S, Davenport G, Doherty M, Forrester H, Jenkins W, Jordan KM, Mallen CD, McDonald T, Nuki G, Pywell A, Zhang W, Roddy E; British Society for Rheumatology Standards, Audit and Guidelines Working Group. The British Society for Rheumatology guideline for the management of gout. Rheumatology (Oxford, England) 2017 Jul;56(7):e1-20.
29. FitzGerald JD, Dalbeth N, Mikuls T, Brignardello-Petersen R, Guyatt C, Abeles AM, Gelber AC, Harrold LR, Khanna D, King C, Levy G, Libbey C, Mount D, Pillinger MH, Rosenthal A, Singh JA, Sims JE, Smith BJ, Wenger NS, Bae SS, Danve A, Khanna PP, Kim SC, Lenert A, Poon S, Qasim A, Sehra ST, Sharma TSK, Toprover M, Turgunbaev M, Zeng L, Zhang MA, Turner AS, Neogi T. 2020 American College of Rheumatology guideline for the management of gout. Arthritis Care & Research 2020 Jun;72(6):744-60.
30. Ministry of Health of the Russian Federation; Association of Rheumatologists of Russia. Gout. Clinical recommendations. ICD 10: M10.0/M10.1/M10.2/M10.3/M10.4/M10.9. Year of approval (frequency of revision): 2018 (1 time in 3 years). Moscow, 2018. 49 p. (In Russian).
31. Stamp LK, Taylor WJ, Jones PB, Dockerty JL, Drake J, Frampton C, Dalbeth N. Starting dose is a risk factor for allopurinol hypersensitivity syndrome: a proposed safe starting dose of allopurinol. Arthritis and Rheumatism 2012 Aug;64(8):2529-36.
32. Schumacher HR Jr, Becker MA, Lloyd E, MacDonald PA, Lademacher C. Febuxostat in the treatment of gout: 5-yr findings of the FOCUS efficacy and safety study. Rheumatology (Oxford, England) 2009 Feb;48(2):188-94.
33. Becker MA, Schumacher HR, MacDonald PA, Lloyd E, Lademacher C. Clinical efficacy and safety of successful longterm urate lowering with febuxostat or allopurinol in subjects with gout. The Journal of Rheumatology 2009 Jun;36(6):1273-82.
34. Whelton A, MacDonald PA, Chefo S, Gunawardhana L. Preservation of renal function during gout treatment with febuxostat: a quantitative study. Postgraduate Medicine 2013 Jan;125(1):106-14.
35. Whelton A, Macdonald PA, Zhao L, Hunt B, Gunawardhana L. Renal function in gout: long-term treatment effects of febuxostat. Journal of Clinical Rheumatology 2011 Jan;17(1):7-13.
36. Saag KG, Whelton A, Becker MA, MacDonald P, Hunt B, Gunawardhana L. Impact of febuxostat on renal function in gout patients with moderate-to-severe renal impairment. Arthritis and Rheumatology 2016;68(8):2035-43.
37. Perez-Ruiz F, Calabozo M, Herrero-Beites A, García-Erauskin G, Pijoan JI. Improvement of renal function in patients with chronic gout after proper control of hyperuricaemia and gouty bouts. Nephron 2000 Nov;86(3):287-91.
38. Ohno I, Ichida K, Okabe H, Hikita M, Uetake D, Kimura H, Saikawa H, Hosoya T. Frequency of gouty arthritis in patients with end-stage renal disease in Japan. Internal Medicine (Tokio, Japan) 2005 Jul;44(7):706-9.
39. Ejaz AA, Nakagawa T, Kanbay M, Kuwabara M, Kumar A, Arroyo FEG, Roncal-Jimenez C, Sasai F, Kang DH, Jensen T, Hernando AA, Rodriguez-Iturbe B, Garcia G, Tolan DR, Sanchez-Lozada LG, Lanaspa MA, Johnson RJ. Hyperuricemia in kidney disease: a major risk factor for cardiovascular events, vascular calcification, and renal damage. Seminars in Nephrology 2020 Nov;40(6):574-85.
40. Kanji T, Gandhi M, Clase CM, Yang R. Urate lowering therapy to improve renal outcomes in patients with chronic kidney disease: systematic review and meta-analysis. BMC Nephrology 2015 Apr;16:58.
41. Foody JA, Turpin RS, Tidwell BA, Lawrence D, Schulman KL. Major cardiovascular events in patients with gout and associated cardiovascular disease or heart failure and chronic kidney disease initiating a xanthine oxidase inhibitor. American Health & Drug Benefits 2017 Nov;10(8):393-401.
42. Gao L, Wang B, Pan Y, Cheng R. Cardiovascular safety of febuxostat compared to allopurinol for the treatment of gout: a systematic and meta-analysis. Clinical Cardiology 2021 Jul;44(7):907-16.
  

[ Содержание выпуска N 3 | Выпуски журнала | Список журналов ]